Transcode Therapeutics Stock Annual Yield
| RNAZ Stock | USD 11.40 0.10 0.87% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Transcode Therapeutics' long-term financial health and intrinsic value.
Transcode | Annual Yield | Build AI portfolio with Transcode Stock |
Transcode Therapeutics Company Annual Yield Analysis
Transcode Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Transcode Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Transcode Therapeutics is extremely important. It helps to project a fair market value of Transcode Stock properly, considering its historical fundamentals such as Annual Yield. Since Transcode Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Transcode Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Transcode Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Transcode Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Transcode Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Transcode Therapeutics from analyzing Transcode Therapeutics' financial statements. These drivers represent accounts that assess Transcode Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Transcode Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 21.8B | 13.8B | 5.6B | 23.1M | 23.5M | 22.4M | |
| Enterprise Value | 21.8B | 13.8B | 5.6B | 20.8M | 17.8M | 16.9M |
Transcode Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Transcode Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Transcode Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Transcode Fundamentals
| Return On Equity | -3.43 | ||||
| Return On Asset | -0.95 | ||||
| Current Valuation | 3.83 M | ||||
| Shares Outstanding | 833.68 K | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 9.09 % | ||||
| Number Of Shares Shorted | 54.46 K | ||||
| Price To Book | 0.93 X | ||||
| EBITDA | (16.19 M) | ||||
| Net Income | (16.75 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 38.29 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 12.35 X | ||||
| Cash Flow From Operations | (13.34 M) | ||||
| Short Ratio | 2.16 X | ||||
| Earnings Per Share | (792.40) X | ||||
| Target Price | 10.0 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 9.59 M | ||||
| Total Asset | 7.29 M | ||||
| Retained Earnings | (63.2 M) | ||||
| Working Capital | 4.32 M | ||||
| Net Asset | 7.29 M |
About Transcode Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transcode Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transcode Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transcode Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.